COMPANY DECK
Gero presentation
Please note, we will consider providing you with a presentation only if you use your full name and corporate e-mail.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Physicist-turned-biotech innovator, Peter Fedichev is the CEO of Gero, a company he co-founded to combat aging and complex diseases. A top-cited physicist with a PhD from the University of Amsterdam and over 75 publications, he uses his deep expertise in physics and data science to drive innovation at the intersection of AI and human health, leveraging over 20 years of experience.
Biotech entrepreneur with 20+ years of experience, Max co-founded Gero to fight aging and age-related disease. He leads corporate affairs, legal strategy, fundraising, and investor relations, holding master's degrees in law and economics. He has initiated and closed multiple partnering, licensing, and investment deals, driven by a mission to extend healthy human lifespan through science-enabled progress.
.png)
Olga leads preclinical research and external R&D collaborations at Gero, supporting the advancement of the company’s therapeutic pipeline. With a Ph.D. in molecular biology, she brings deep expertise in target validation, pharmacology, translational biology, and experimental drug development. She has authored multiple peer-reviewed publications and has extensive experience managing complex preclinical programs across academia and industry. Olga is deeply interested in the biology of aging and is passionate about driving innovative translational projects that have the potential to extend healthy lifespan.
Experienced tech entrepreneur and operational leader with multiple exits, including to Samsung. Aleksandr brings over a decade of expertise managing multidisciplinary teams and driving ambitious projects from concept to successful outcomes. As a longevity maximalist, he is deeply committed to Gero’s mission of stopping aging and chronic diseases through cutting-edge biotech and AI innovation.
Serial tech entrepreneur and investor with a proven track record of successful exits, including acquisitions by Google, Pinterest, and Farfetch. Yuri brings deep expertise in Machine Learning, Computer Vision, and AI, coupled with a proven ability to lead companies toward sustained growth and strategic exits.
Globally renowned longevity researcher, Distinguished Professor of Biochemistry & Physiology at the National University of Singapore, and Director of the Centre for Healthy Longevity at the National University Health System (NUHS). Brian previously served as President and CEO of the Buck Institute for Research on Aging, the premier independent aging research center in the U.S. He also holds adjunct professorship at USC’s Leonard Davis School of Gerontology, among other academic roles. Brian brings deep expertise in translating cutting-edge science into transformative therapies against aging and age-related diseases.
.jpeg)
Eileen is leading the company's commercial and technical IP legal work. Eileen previously worked in the same capacity at NASDAQ listed TechBio company Exscientia AI (now Recursion Pharmaceuticals).
Biotechnology leader with over 30 years of international drug discovery experience across the UK, Canada, and Asia. Previously held senior executive and scientific leadership positions including President of Scotia Pharmaceuticals Canada, Wellcome Research (GSK), Xenon Pharmaceuticals (Canada), Engine Biosciences (Singapore) and Genome Institute of Singapore, as well as adjunct positions at NUS and NTU. Managed established global research alliances with Novartis, Merck, and Ionis.
A pioneer in in silico drug design and computational medicinal chemistry, Paulette brings 25+ years of drug discovery experience with affiliations spanning Oxford, ETH Zurich, and the Institute of Cancer Research. A Fellow of the Royal Society of Chemistry with a PhD in Theoretical Chemistry from the University of Manchester, she has worked across both big pharma (Novartis/NIBR) and biotech startups. She holds 11 granted WIPO patents and 22 peer-reviewed publications, and applies AI/ML to revolutionize precision-medicine drug discovery.
Computational biologist and AI drug discovery leader with experience across pharma, biotech, and AI-enabled startups. Amir leads Translational AI and Target Discovery at Gero, integrating longitudinal human health models, statistical genetics, multi-omics, and translational biology to identify targets for aging-related and complex diseases. Previously, he held roles at Novo Nordisk and OMass Therapeutics, an Oxford University spin-out, and contributed to genetics-led discovery programs across cardiometabolic and immune-inflammatory indications. Amir holds a PhD in Systems Biology and Bioinformatics from Chalmers University of Technology and has published in Science, Nature, and Cell.
Founder and COO at Connected Discovery Ltd., Ex SVP of Drug Discovery at Benevolent AI.
Medicinal Chemist, Ex-Eli Lilly and WuXi AppTec
Medicinal Chemistry at Pfizer, Co-inventor of XELJANZ and CIBINQO
Professor at The University of Salamanca
Associate Professor at the National University of Singapore
